Literature DB >> 20117861

PEG-scutellarin prodrugs: synthesis, water solubility and protective effect on cerebral ischemia/reperfusion injury.

Juan Lu1, Changmei Cheng, Xinge Zhao, Qingfei Liu, Ping Yang, Yiming Wang, Guoan Luo.   

Abstract

Fifteen PEG-scutellarin prodrugs were synthesized by modifying carboxyl and phenolic hydroxyl groups of scutellarin with mPEG of different molecular weight (400-3000). The water solubility of prodrugs increased remarkably and reached the maximum value of 783.88 mg/mL (scutellarin, 0.02 mg/mL). The anti-infarct effects of four PEG prodrugs with high water solubility were evaluated by Cerebral Ischemia/Reperfusion in the Middle Cerebral Artery Occlusion (MCAO) model. The results showed that the prodrug 7e could significantly reduce the infarct area from 27.2% to 12.2% (33.3% for the control) and decrease the neurological deficit score from 2.77 to 1.32 (2.85 for the control). The half-life (18.62 min) of the prodrug 7e was significantly longer than that of scutellarin (3.03 min). Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117861     DOI: 10.1016/j.ejmech.2010.01.006

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  9 in total

Review 1.  Phthalimide analogs for antimalarial drug discovery.

Authors:  Meenakshi Bansal; Charu Upadhyay; Sumit Kumar; Brijesh Rathi
Journal:  RSC Med Chem       Date:  2021-08-13

2.  Solid dispersion tablets of breviscapine with polyvinylpyrrolidone K30 for improved dissolution and bioavailability to commercial breviscapine tablets in beagle dogs.

Authors:  Wenjuan Cong; Lan Shen; Desheng Xu; Lijie Zhao; Kefeng Ruan; Yi Feng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-09-06       Impact factor: 2.441

3.  Method parameters' impact on mortality and variability in rat stroke experiments: a meta-analysis.

Authors:  Jakob O Ström; Edvin Ingberg; Annette Theodorsson; Elvar Theodorsson
Journal:  BMC Neurosci       Date:  2013-04-01       Impact factor: 3.288

Review 4.  Therapeutic Effects of Breviscapine in Cardiovascular Diseases: A Review.

Authors:  Jialiang Gao; Guang Chen; Haoqiang He; Chao Liu; Xingjiang Xiong; Jun Li; Jie Wang
Journal:  Front Pharmacol       Date:  2017-05-23       Impact factor: 5.810

5.  Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.

Authors:  Jingnan Wang; Jiayun Tan; Jiahao Luo; Peilin Huang; Wuyi Zhou; Luming Chen; Lingli Long; Li-Ming Zhang; Banghao Zhu; Liqun Yang; David Y B Deng
Journal:  J Nanobiotechnology       Date:  2017-03-01       Impact factor: 10.435

Review 6.  Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases.

Authors:  Mahvash Hesari; Pantea Mohammadi; Fatemeh Khademi; Dareuosh Shackebaei; Saeideh Momtaz; Narges Moasefi; Mohammad Hosein Farzaei; Mohammad Abdollahi
Journal:  Int J Nanomedicine       Date:  2021-05-11

7.  Intravenous Administration of Scutellarin Nanoparticles Augments the Protective Effect against Cerebral Ischemia-Reperfusion Injury in Rats.

Authors:  Chang Yang; Qing Zhao; Shanshan Yang; Libin Wang; Xingyuan Xu; Lisu Li; Wafa T Al-Jamal
Journal:  Mol Pharm       Date:  2022-04-20       Impact factor: 5.364

8.  Neutrophil-mediated and low density lipoprotein receptor-mediated dual-targeting nanoformulation enhances brain accumulation of scutellarin and exerts neuroprotective effects against ischemic stroke.

Authors:  Yanxin Dang; Chiying An; Yutao Li; Dandan Han; Xin Liu; Fengming Zhang; Yuan Xu; Haijing Zhong; Mewand Khan Karim Khan; Fengjuan Zou; Xiaojun Sun
Journal:  RSC Adv       Date:  2019-01-10       Impact factor: 4.036

9.  Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism.

Authors:  Xinran Wang; Cai Zhang; Ning Han; Juyuan Luo; Shuofeng Zhang; Chunguo Wang; Zhanhong Jia; Shouying Du
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.